Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novo Nordisk licenses ghrelin antagonist program to Sapphire for treatment of obesity

Nov. 6, 2007

FDA accepts Indevus Pharmaceuticals' NDA for Nebido for male hypogonadism

Nov. 5, 2007

Lev amends Cinryze BLA for the treatment of hereditary angioedema

Nov. 5, 2007

Sciele and Plethora initiate patient enrollment in phase III trials of PSD-502

Nov. 2, 2007

Pharming completes randomized treatments in clinical trial of Rhucin

Nov. 2, 2007

Epix reports positive results from phase IIb clinical trial of PRX-07034 in obesity

Nov. 2, 2007

FDA recommends suspension of clinical studies with higher doses of TAK-475

Oct. 31, 2007

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

Oct. 31, 2007

Recent Novo Nordisk patent discloses novel antiobesity agents

Oct. 30, 2007

Unigene successfully completes oral calcitonin study

Oct. 30, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...